ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jan 2022
Last Updated on 12 Jul 2022
A- A+
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
  • Cetuximab 100 mg/20 mL solution for infusion; and
  • Panitumumab 100 mg/5 mL concentrate for solution for infusion

as monotherapy or in combination with chemotherapy for treating RAS wild-type metastatic colorectal cancer.

Subsidy status

Panitumumab 100 mg/5 mL concentrate for solution for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.

Cetuximab 100 mg/20 mL solution for infusion is recommended for inclusion on the SDL for the abovementioned indication with effect from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.


Cetuximab and panitumumab for treating RAS wild-type CRC (12 Jul 22) Treatments for RAS wild-type metastatic CRC PES (12 Jul 22)